SCHEMBL9702240

SCHEMBL9702240

O=C(/C=C/c1cccc(F)c1)c1ccc(O)cc1O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.71
MEN1 O00255 3/20 0.71
KMT2A Q03164 3/20 0.71
MAPT P10636 2/20 0.71
HPGD P15428 2/20 0.71
ALOX15 P16050 2/20 0.71
MAPK1 P28482 2/20 0.71
HSD17B10 Q99714 2/20 0.71
TDP1 Q9NUW8 2/20 0.71
KDM4E B2RXH2 1/20 0.71
ALDH1A1 P00352 1/20 0.71
THRB P10828 1/20 0.71
SMN1; SMN2 Q16637 1/20 0.71
ABCG2 Q9UNQ0 3/20 0.66
NR1H4 Q96RI1 1/20 0.66
NFKB1 P19838 3/20 0.66
CYP2C9 P11712 2/20 0.66
CYP2C19 P33261 2/20 0.66
AKR1B1 P15121 2/20 0.66
HSD17B2 P37059 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9702245 1.00 CYP3A4 (0.71) CYP3A4MEN1KMT2AMAPTHPGD
SCHEMBL30382897 1.00 CYP3A4 (0.71) CYP3A4MEN1KMT2AMAPTHPGD
SCHEMBL25195193 0.90 MEN1 (0.82) CYP3A4MEN1KMT2AMAPTHPGD
SCHEMBL28093997 0.90 MEN1 (0.82) CYP3A4MEN1KMT2AMAPTHPGD
SCHEMBL4953081 0.89 GUSB (0.71) MEN1KMT2AMAPTHPGDALOX15
SCHEMBL14027262 0.88 MEN1 (0.79) CYP3A4MEN1KMT2AMAPTHPGD
SCHEMBL25194592 0.88 MEN1 (0.79) CYP3A4MEN1KMT2AMAPTHPGD
SCHEMBL30383752 0.88 MEN1 (0.79) CYP3A4MEN1KMT2AMAPTHPGD
SCHEMBL25185058 0.85 ABCG2 (0.81) CYP3A4MEN1KMT2AMAPTHPGD
SCHEMBL30383219 0.85 ABCG2 (0.81) CYP3A4MEN1KMT2AMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
EP-0502205-A1 CHALCONE DERIVATIVE AND ULTRAVIOLET SCREENING COSMETIC NIPPON HYPOX LABORATORIES INCORPORATED (JP) 1992-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B CYP3A4 928/4885MEN1 3367/4885KMT2A 2792/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 CYP3A4 1589/4885MEN1 2457/4885KMT2A 3188/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 CYP3A4 1589/4885MEN1 2457/4885KMT2A 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.